Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright

Abeona Therapeutics highlighted early commercial progress for ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa, at the H.C. Wainwright 28th Annual Conference. The update signals initial commercialization momentum for the rare-disease gene therapy, though no revenue, patient-treatment, or guidance figures were disclosed.